Physician profile
John Kliesch
NPI 1679538326
$1,396.18
in general payments reported to CMS, 2019-2025
26 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.75 · 2020: $52.56 · 2021: $62.77 · 2022: $383 · 2023: $346 · 2024: $396 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $222.65 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $136.76 | 2024-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $103.22 | 2022-2023 | Uptravi, Opsumit |
| Paratek Pharmaceuticals, INC. | $101.96 | 2022-2024 | Nuzyra |
| Glaxosmithkline, LLC. | $101.69 | 2023-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Philips North America LLC | $73.67 | 2022-2023 | |
| Electromed, INC. | $72.97 | 2022-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $62.69 | 2022-2023 | Breztri, Fasenra |
| Genentech USA, INC. | $59.56 | 2019-2021 | |
| Harmony Biosciences LLC | $58.71 | 2022-2023 | Wakix |
| Inogen, INC. | $49.73 | 2023-2024 | Inogen At Home Stationary Concentrator |
| Regeneron Healthcare Solutions, INC. | $49.69 | 2024 | Dupixent |
| Abbvie INC. | $34.59 | 2021 | |
| Lilly USA, LLC | $32.41 | 2025 | Zepbound |
| Mylan Specialty L.P. | $28.35 | 2022-2024 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $25.22 | 2022 | |
| Axsome Therapeutics, INC. | $23.23 | 2023 | Sunosi |
| La Jolla Pharmaceutical Company | $22.96 | 2024 | Xacduro |
| Grifols USA, LLC | $21.40 | 2024 | Prolastin-C Liquid |
| Shield Therapeutics INC | $19.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.44 | 2023 | Ofev |
| Allergan, INC. | $18.26 | 2020 | |
| 3b Medical, INC. | $17.34 | 2025 | Luna |
| Biohaven Pharmaceuticals, INC. | $15.19 | 2021 | |
| Neurocrine Biosciences, INC. | $14.59 | 2024 | Ingrezza |
| Circassia INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kliesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.